Molecular Biomarkers and the Future of Bladder Cancer Assessment

Published on
November 15, 2026

Department of Genetics, Maharshi Dayanand University, Rohtak, Haryana, India

Areas of Expertise
Human genetics, Cancer Biomarkers, Genetic Polymorphism

Bladder cancer does not behave in the same way in every patient. Even when clinical and pathological features appear similar, patients may differ considerably in recurrence, disease progression and response to treatment. Cystoscopy, imaging and histopathological examination therefore remain central to diagnosis and follow-up. At the same time, advances in molecular biology are providing additional information about the biological differences that exist between tumours.

Molecular biomarkers are of interest because they can capture changes that may not be evident from conventional clinical assessment alone. Genetic variants, tumour-associated molecular alterations, circulating proteins and tumour-derived DNA are all being investigated for their possible roles in detection, risk assessment, disease monitoring and treatment selection. The important question, however, is not simply whether a biomarker is associated with bladder cancer. Its real value depends on whether the finding can be reproduced and whether it adds useful information to clinical decision-making.

Bladder cancer develops through a combination of genetic and biological events. Alterations in cell growth, inflammation, tissue remodelling and angiogenesis can all contribute to the development and progression of the disease. Because several processes operate simultaneously, it is unlikely that one biomarker will adequately describe the complete biological behaviour of bladder cancer.

Vascular endothelial growth factor A (VEGFA) is one molecular factor that has received considerable attention. It plays an important role in angiogenesis, the process through which new blood vessels are formed. Changes in tumour growth and in the surrounding microenvironment can influence the demand for blood supply, making angiogenic pathways relevant to cancer progression.

Another molecule of interest is YKL-40, also known as chitinase-3-like protein 1 (CHI3L1). YKL-40 is a circulating protein associated with inflammation and tissue remodelling. Its possible role in bladder cancer has been investigated previously. In a case-control study, serum YKL-40 concentrations were reported to be higher in patients with bladder cancer than in healthy controls, while urinary YKL-40 was also associated with invasive disease.

Our recent study examined YKL-40 in relation to genetic variation in VEGFA. The study included 120 patients with bladder cancer and 120 age- and sex-matched controls. We investigated the VEGFA rs833061 (-460T>C) promoter polymorphism together with serum YKL-40 concentrations. Differences in VEGFA genotype distribution were observed between patients and controls. Serum YKL-40 was also higher among patients, and its concentration varied according to VEGFA genotype.

The significance of these observations lies partly in the fact that the two markers provide different types of biological information. A genetic polymorphism reflects inherited variation, whereas a circulating protein can provide an indication of biological activity occurring in the disease setting. Considering these measurements together may therefore provide a more informative picture than examining either marker independently.

Liquid biopsy has become an important area of investigation in molecular oncology. Tumours can release DNA and other biological material into body fluids, allowing researchers to examine molecular features without relying exclusively on tissue obtained through an invasive procedure.

Circulating tumour DNA (ctDNA) is particularly interesting because it can contain molecular information originating from tumour cells. Studies are exploring its potential for assessing tumour burden, identifying molecular alterations and following molecular changes during treatment.

Bladder cancer has a particular advantage in this area because urine is directly associated with the urinary tract. Urinary DNA, RNA, proteins and other molecular components can therefore be investigated as potential sources of disease-related information. Blood and urine can also be collected repeatedly, which creates an opportunity to monitor molecular changes over time.

There are nevertheless important limitations. The amount of tumour-derived material present in a sample may differ between patients and may also depend on disease stage. Sample collection and storage, laboratory processing and the analytical platform used can affect the final result. For this reason, promising liquid-biopsy markers still require careful analytical and clinical validation before they can be incorporated into routine practice.

Recent recommendations from the International Bladder Cancer Group have emphasized the growing role of biomarkers while also stressing the importance of prospective validation, standardized testing and demonstrated clinical utility. The recommendations also point to opportunities for ctDNA-based testing and molecular assessment of actionable alterations, including FGFR3, in suitable clinical settings.

One of the major difficulties in molecular oncology is moving a promising biomarker from the research laboratory into clinical practice.

A statistically significant association is an important starting point, but it does not by itself establish that a biomarker is ready for clinical use. Findings need to be reproduced in independent patient populations, and the performance of the test should remain acceptable under different clinical and laboratory conditions.

Clinical relevance is equally important. A biomarker becomes more useful when its result can contribute to a specific clinical decision. In bladder cancer, this could involve improving risk assessment, helping to monitor disease or identifying patients who may be suitable for a particular treatment.

YKL-40 illustrates this distinction well. Increased YKL-40 concentrations among patients with bladder cancer support its biological and diagnostic interest. However, additional studies are required to establish how consistently the marker performs across different populations and disease stages. It is also important to determine whether YKL-40 provides information beyond that already obtained from established clinical and pathological characteristics.

Genetic biomarkers face a similar challenge. An association between a genetic variant and cancer risk does not necessarily demonstrate a causal relationship, nor does it automatically establish clinical usefulness. Replication in independent populations, functional investigation and prospective evaluation are needed before such findings can be translated into routine clinical testing.

The direction of bladder cancer research is increasingly moving toward the combined interpretation of multiple molecular features. Rather than expecting one biomarker to provide a complete assessment, future approaches may bring together several types of information.

A potential molecular profile could include inherited genetic variants, tumour-associated mutations, circulating proteins, ctDNA, urinary biomarkers and conventional clinical information. Such an approach may help explain why patients with apparently similar clinical characteristics can nevertheless have different disease courses.

Computational biology may also contribute to this process. Large molecular datasets contain relationships that can be difficult to recognize when individual biomarkers are examined separately. With appropriate validation, computational approaches may help identify combinations of molecular features that are associated with clinically meaningful outcomes.

At the same time, adding more biomarkers does not automatically produce a better diagnostic or prognostic tool. A useful panel needs to be reproducible and clinically interpretable. It should also be practical to perform, and the additional cost and complexity should be justified by the information obtained.

For this reason, molecular biomarkers are more likely to complement established clinical methods than replace them. Histopathology, imaging, cystoscopy and clinical assessment will continue to have important roles in bladder cancer management. Molecular testing can provide another layer of information, particularly when the aim is to understand biological differences between tumours or identify patients with different levels of risk.

The next phase of bladder cancer biomarker research will depend on how effectively molecular findings can be connected with clinical needs.

Our observations involving VEGFA and YKL-40 provide one example of this approach. Examining a genetic polymorphism alongside a circulating biomarker allows researchers to consider both genetic variation and disease-associated biological activity. However, these findings need confirmation in larger and multicentre populations before their broader clinical relevance can be established.

Reproducibility, standardization and clinical utility should therefore remain major priorities. Prospective studies and appropriately designed clinical trials will be necessary to determine which molecular markers can make the transition from experimental research to practical clinical application.

It is unlikely that the future of bladder cancer assessment will be based on a single molecular marker. A more realistic direction is the integration of several biological signals with clinical and pathological information. Advances in genomics, liquid biopsy, molecular pathology and computational analysis are making such integrated approaches increasingly possible.

The central challenge is now to translate the growing volume of molecular information into results that are reliable and useful in clinical practice. Biomarkers will have their greatest impact when promising biological observations are supported by rigorous validation and ultimately converted into practical tools that can assist clinicians and improve patient care.

References

Yasar MO, Akcay PD, Obek MC, Turegun MF. Diagnostic potential of YKL-40 in bladder cancer. InUrologic Oncology: Seminars and Original Investigations 2016 Jun 1 (Vol. 34, No. 6, pp. 257-e19). Elsevier.
Article DOI

Kaushik R, Pawar D, Sharma A, Siwach K, Rohilla G, Narwal S, Khatri N, Arora A, Vashist M. Integrated analysis of VEGFA rs833061 (− 460T> C) promoter polymorphism and serum YKL-40 levels in bladder cancer: evidence of a genotype–phenotype association. Molecular Biology Reports. 2026 Dec;53(1):1585.
Article DOI

Hensley PJ, Teoh JY, Li R, Gupta S, Bukavina L, Mouw KW, Lobo N, Maiorano BA, Tan WS, Agarwal P, Al-Ahmadie HA. Integrating clinically actionable biomarkers into bladder cancer care—recommendations from the International Bladder Cancer Group. Nature Reviews Urology. 2026 Aug 5:1-4.
Article DOI

Science Factors.

Evolution of proteins: a stride between stability and flexibility

Dr. N. Prakash Prabhu
0
The evolution of living forms from RNA molecules capable of performing functions and carrying information to more complex, refined systems is a journey of...

Teaching an Old Flavonoid New Tricks: What’s Next for Diabetic Wound Therapeutics

Dr. Suhani Sinha
0
India now has more than 77 million adults living with diabetes, and somewhere between 5% and 14% of these people will develop a foot...

Double Diabetes: When Type 1 Diabetes Meets Insulin Resistance

Dr Satyajeet Khare
0
A child with type 1 diabetes (T1D) whose insulin dose keeps rising while glucose control does not improve may have a second problem: insulin...

Unlocking Natural Tick Resistance in Indigenous Cattle for Sustainable Livestock Farming

Dr. Jay Prakash Gupta
0
Ticks and tick-borne diseases are among the major challenges affecting milk production in India, causing considerable economic losses to dairy farmers. In addition to...

Predicting Molecular Excitations: New Tools for Future Light-Emitting Materials

Dr Manash Protim Borpuzari
0
An electron in a molecule absorbs energy and is excited to an electronically excited state; this is a simple molecular event that is the...

Can “Bioalchemistry” Transform Pharmaceutical Science Towards a Greener and Healthier Tomorrow?

Dr. Anil Kumar Kanuri
0
Pharmaceutical science has always been driven by one fundamental objective: improving human health. Yet, as the demand for medicines continues to increase, an important...

Climate, Catastrophes and the Growing Threat to Lung Health

Dr. Arundhati Garud
0
When a disaster strikes, people's immediate concerns revolve around survival, securing shelter, finding food, and ensuring the safety of their loved ones. However, even...

Five Colourful Crystals of One Molecular Pair: The Hidden Diversity of Pharmaceutical Co-crystals

Dr. Sonali Ghosh
0
At first glance, a crystal may seem like one of the simplest forms of matter. Molecules arrange themselves into an ordered structure, the crystal...